Human Vascular Endothelial Growth Factor-165 (hVEGF₁₆₅ )

• 产品编号：CST-8065LC      品牌：CST       原厂货号：8065LC
• 产品分类：蛋白质检测与分析 > 蛋白质，多肽和酶 > 细胞因子和生长因子 > VEGF血管内皮生长因子
• 应用分类：

描述：

CST公司在人293细胞中生产重组人蛋白VEGF165 (hVEGF₁₆₅) Ala207-Arg371 (Accession #NP_001020539)。重组的hVEGF₁₆₅蛋白没有标签，未糖基化蛋白的分子量据推算为19,165Da。DTT-还原蛋白迁移时是作为24kDa 的多肽而转移。未还原的蛋白通过胱氨酸形成二聚体并作为40kDa 多肽而迁移。重组hVEGF₁₆₅蛋白的N-末端APMAE的序列通过测序得到。6 μg 还原 (+) 和 非还原的(-) hVEGF₁₆₅通过SDS-PAGE检测，纯度大于98%，所有批次的纯度均高于98%。重组蛋白hVEGF₁₆₅的生物活性是通过HUVEC细胞的细胞增殖实验确定的。每个批次的ED50在1-6 ng/ml之间。

有载体: 每微克hVEGF₁₆₅蛋白溶解在包含 20 μg BSA的PBS（pH 7.2）溶液中，并通过 0.22 μm 滤膜冻干。

无载体：每微克hVEGF₁₆₅蛋白溶解在PBS（pH 7.2）溶液中，并通过 0.22 μm 滤膜冻干。VEGF165是VEGF-A不同剪切中数量最丰富的形式(1,2)。VEGF165是通过很多细胞产生包括内皮细胞、巨噬细胞、T细胞。VEGF165参与到了血管再生、血管内皮细胞生存、生长、迁移和血管渗透(1)。VEGF基因的表达受到组织缺氧，炎症因子和肿瘤组织产生的致癌基因的诱导(1-3)。VEGF165结合到硫酸乙酰肝素并返回细胞表面和细胞间质中(2,3)。VEGF165结合到VEGFR1和VEGFR2 受体酪氨酸激酶(1)。VEGF165是唯一能够结合到共受体NRP-1和NRP-2上(1-3)并增强VEGFR2信号(1)。 VEGF165 结合到 VEGFR1和VEGFR2导致了信号通路的激活，如PI3K/AKT、P38 MAPK和桩蛋白(1)。在很多癌症中，VEGF在肿瘤血管再生中发挥了重要的作用(2)。

原厂资料：

Source / Purification

Recombinant human VEGF165 (hVEGF165) Ala207-Arg371 (Accession #NP_001020539) was expressed in human 293 cells at Cell Signaling Technology.

Molecular Characterization

Recombinant hVEGF165 contains no "tags" and has a calculated MW of 19,165. DTT-reduced protein migrates as a 24 kDa polypeptide and the non-reduced cystine-linked homodimer migrates as a 40 kDa protein. The expected amino-terminal APMAE of recombinant hVEGF165 was verified by amino acid sequencing.

Purity

>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hVEGF165. All lots are greater than 98% pure.

Bioactivity

The bioactivity of recombinant hVEGF165 was determined in a cell proliferation assay using HUVEC. The ED50 of each lot is between 1-6 ng/ml.

Endotoxin

Less than 0.01 ng endotoxin/1μg hVEGF165.

Formulation

With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg hVEGF165. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2.

Background

VEGF165 is the most abundant splice variant of VEGF-A (1,2). VEGF165 is produced by a number of cells including endothelial cells, macrophages and T cells. VEGF165 is involved in angiogenesis, vascular endothelial cell survival, growth, migration and vascular permeability (1). VEGF gene expression is induced by hypoxia, inflammatory cytokines and oncogenes (1,2). VEGF165 binds to heparan sulfate and is retained on the cell surface and in the extracellular matrix (2,3). VEGF165 binds to the receptor tyrosine kinases, VEGFR1 and VEGFR2 (1). VEGF165 is the only splice variant that binds to co-receptors NRP-1 and NRP-2 (1-3) that function to enhance VEGFR2 signaling (1). Binding of VEGF165 to VEGFR1 and VEGFR2 leads to activation of the PI3K/AKT, p38 MAPK, FAK and paxillin (1). VEGF plays a key role in tumor angiogenesis in many cancers (2).

注意事项：

Storage: Stable in lyophilized state at 4ºC for 1 year after
receipt. Sterile stock solutions reconstituted with carrier protein
are stable at 4ºC for 2 months and at -20ºC for 6 months. Avoid
repeated freeze-thaw cycles.